Clinical Implications of the p53 Tumor-Suppressor Gene

New England Journal of Medicine

Volumn 329, Issue 18, 1993, Pages 1318-1327

  Harris, Curtis C ^a   Hollstein, Monica ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53;

CELL CYCLE; CHROMOSOME MAP; DNA DAMAGE; GENE MUTATION; GENETIC SCREENING; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION REGULATION; TREATMENT PLANNING; TUMOR SUPPRESSOR GENE;

GENE DELETION; GENES, TUMOR SUPPRESSOR; HUMAN; MUTATION; NEOPLASMS; PROTEIN P53; TRANSCRIPTION, GENETIC;

EID: 0027489384     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199310283291807     Document Type: Review

References (136)

1. Weinberg RA Tumor suppressor genes. Science 1991; 254: 1138-1146
2. Latif F, Tory K, Gnarra J, Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-1320
3. Trofatter JA, MacCollin MM, Rutter JL, A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72: 791-800
4. Rouleau GA, Merel P, Lutchman M, Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363: 515-521
5. Schimke RN. Genetics and cancer in man. Edinburgh, Scotland: Churchill Livingstone, 1978:18, 26, 70.
6. Lasko D, Cavenee W, Nordenskjold M Loss of constitutional heterozygosity in human cancer. Annu Rev Genet 1991; 25: 281-314
7. Bishop JM Molecular themes in oncogenesis. Cell 1991; 64: 235-248
8. Brugge J, Curran T, Harlow E, McCormick F, eds. Origins of human cancer: a comprehensive review. Plainview, N.Y.: Cold Spring Harbor Laboratory, 1991.
9. Harris CC Chemical and physical carcinogenesis: advances and perspectives for the 1990s. Cancer Res 1991; 51: Suppl: 5023s-5044s
10. Lane DP, Crawford LV T antigen is bound to a host protein in SV40-transformed cells. Nature 1979; 278: 261-263
11. Linzer DI, Levine AJ Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979; 17: 43-52
12. Levine AJ, Momand J, Finlay CA The p53 tumour suppressor gene. Nature 1991; 351: 453-456
13. Hollstein M, Sidransky D, Vogelstein B, Harris CC p53 Mutations in human cancers. Science 1991; 253: 49-53
14. Rotter V, Prokocimer M p53 and Human malignancies. Adv Cancer Res 1991; 57: 257-272
15. Oren M p53: The ultimate tumor suppressor gene? FASEB J 1992; 6: 3169-3176
16. Caron de Fromentel C, Soussi T TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992; 4: 1-15
17. Montenarh M Biochemical properties of the growth suppressor/oncoprotein p53. Oncogene 1992; 7: 1673-1680
18. Vogelstein B, Kinzler KW p53 Function and dysfunction. Cell 1992; 70: 523-526
19. Dutta A, Ruppert JM, Aster JC, Winchester E Inhibition of DNA replication factor RPA by p53. Nature 1993; 365: 79-82
20. Pietenpol JA, Vogelstein B No room at the p53 inn. Nature 1993; 365: 17-18
21. Lane DP, Benchimol S p53: Oncogene or anti-oncogene? Genes Dev 1990; 4: 1-8
22. Seto E, Usheva A, Zambetti GP, Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A 1992; 89: 12028-12032
23. Mack DH, Vartikar J, Pipas JM, Laimins LA Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type p53. Nature 1993; 363: 281-283
24. Shiio Y, Yamamoto T, Yamaguchi N Negative regulation of Rb expression by the p53 gene product. Proc Natl Acad Sci U S A 1992; 89: 5206-5210
25. Agoff SN, Hou J, Linzer DI, Wu B Regulation of the human hsp70 promoter by p53. Science 1993; 259: 84-87
26. Deffie A, Wu H, Reinke V, Lozano G The tumor suppressor p53 regulates its own transcription. Mol Cell Biol 1993; 13: 3415-3423
27. Hupp TR, Meek DW, Midgley CA, Lane DP Regulation of the specific DNA binding function of p53. Cell 1992; 71: 875-886
28. Ullrich SJ, Anderson CW, Mercer WE, Appella E The p53 tumor suppressor protein, a modulator of cell proliferation. J Biol Chem 1992; 267: 15259-15262
29. Oliner JD, Pietenpol JA, Thiagalingam S, Gyuris J, Kinzler KW, Vogelstein B Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53. Nature 1993; 362: 857-860
30. Momand J, Zambetti GP, Olson DC, George D, Levine AJ The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 1992; 69: 1237-1245
31. Oliner JD, Kinzler KW, Meltzer PS, George DL, Vogelstein B Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992; 358: 80-83
32. Leach FS, Tokino T, Meltzer P, p53 Mutation and MDM2 amplification in human soft tissue sarcomas. Cancer Res 1993; 53: Suppl: 2231-2234
33. Maheswaran S, Park S, Bernard A, Physical and functional interaction between WT1 and p53 proteins. Proc Natl Acad Sci U S A 1993; 90: 5100-5104
34. Howley PM Role of the human papillomaviruses in human cancer. Cancer Res 1991; 51: Suppl: 5019s-5022s
35. Loeb LA Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 1991; 51: 3075-3079
36. Watson JD, Hopkins NH, Roberts JW, Steitz JA, Weiner AM. Molecular biology of the gene. 4th ed. Menlo Park, Calif.: Benjamin/Cummings, 1987.
37. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 923-935
38. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70: 937-948
39. Peltomaki P, Aaltonen LA, Sistonen P, Genetic mapping of a locus predisposing to human colorectal cancer. Science 1993; 260: 810-812
40. Aaltonen LA, Peltomaki P, Leach FS, Clues to the pathogenesis of familial colorectal cancer. Science 1993; 260: 812-816
41. Thibodeau SN, Bren G, Schaid D Microsatellite instability in cancer of the proximal colon. Science 1993; 260: 816-819
42. Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993; 363: 558-561
43. Schwartz D, Goldfinger N, Rotter V Expression of p53 protein in spermatogenesis is confined to the tetraploid pachytene primary spermatocytes. Oncogene 1993; 8: 1487-1494
44. Kastan MB, Zhan Q, el-Deiry WS, A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992; 71: 587-597
45. Hall PA, McKee PH, Menage HD, Dover R, Lane DP High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993; 8: 203-207
46. Hartwell L Defects in a cell cycle checkpoint may be responsible for the genomic instability of cancer cells. Cell 1992; 71: 543-546
47. Lane DP A death in the life of p53. Nature 1993; 362: 786-787
48. Clarke AR, Purdie CA, Harrison DJ, Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993; 362: 849-852
49. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T p53 Is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-849
50. Lee JM, Bernstein A p53 Mutations increase resistance to ionizing radiation. Proc Natl Acad Sci U S A 1993; 90: 5742-5746
51. Gannon JV, Greaves R, Iggo R, Lane DP Activating mutations in p53 produce a common conformational effect: a monoclonal antibody specific for the mutant form. EMBO J 1990; 9: 1595-1602
52. Bartek J, Bartkova J, Vojtesek B, Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6: 1699-1703
53. Miyoshi Y, Nagase H, Ando H, Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992; 1: 229-233
54. Horii A, Nakatsuru S, Miyoshi Y, The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res 1992; 52: 3231-3233
55. Lehman TA, Harris CC. Mutational spectra of protooncogenes and tumor suppressor genes: clues to predict cancer etiology. IARC Monogr Eval Carcinog Risks Hum (in press).
56. Cheng KC, Loeb LA Genomic instability and tumor progression: mechanistic considerations. Adv Cancer Res 1993; 60: 121-156
57. Miller JH Mutational specificity in bacteria. Annu Rev Genet 1983; 17: 215-238
58. Thilly WG Mutational spectrometry in animal toxicity testing. Annu Rev Pharmacol Toxicol 1990; 30: 369-385
59. Horsfall MJ, Gordon AJ, Burns PA, Zielenska M, van der Vliet GM, Glickman BW Mutational specificity of alkylating agents and the influence of DNA repair. Environ Mol Mutagen 1990; 15: 107-122
60. Jones PA, Buckley JD, Henderson BE, Ross RK, Pike MC From gene to carcinogen: a rapidly evolving field in molecular epidemiology. Cancer Res 1991; 51: 3617-3620
61. Vogelstein B, Kinzler KW Carcinogens leave fingerprints. Nature 1992; 355: 209-210
62. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428
63. Bressac B, Kew M, Wands J, Ozturk M Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991; 350: 429-431
64. Ross RK, Yuan JM, Yu MC, Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 1992; 339: 943-946
65. Wu-Williams AH, Zeise L, Thomas D Risk assessment for aflatoxin B1: a modeling approach. Risk Anal 1992; 12: 559-567
66. Harris CC. p53 Mutational spectrum and molecular epidemiology of human cancer. In: Fortner JC, Rhoads JE, eds. Accomplishments in cancer research 1992. Philadelphia: J.B. Lippincott, 1993:179-88.
67. Yap EP, Cooper K, Maharaj B, McGee JO p53 Codon 249ser hot-spot mutation in HBV-negative hepatocellular carcinoma. Lancet 1993; 341: 251-251
68. Trottier Y, Waithe WI, Anderson A Kinds of mutations induced by aflatoxin B1 in a shuttle vector replicating in human cells transiently expressing cytochrome P4501A2 cDNA. Mol Carcinog 1992; 6: 140-147
69. Levy DD, Groopman JD, Lim SE, Seidman MM, Kraemer KH Sequence specificity of aflatoxin B1-induced mutations in a plasmid replicated in xeroderma pigmentosum and DNA repair proficient human cells. Cancer Res 1992; 52: 5668-5673
70. Lilleberg SL, Cabonce MA, Raju NR, Wagner LM, Kier LD Alterations in the structural gene and the expression of p53 in rat liver tumors induced by aflatoxin B1. Mol Carcinog 1992; 6: 159-172
71. Foster PL, Eisenstadt E, Miller JH Base substitution mutations induced by metabolically activated aflatoxin B1. Proc Natl Acad Sci U S A 1983; 80: 2695-2698
72. 1 induces the transversion of G-to-T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 1993; 90: 8586-8590
73. Drobetsky EA, Grosovsky AJ, Glickman BW The specificity of UV-induced mutations at an endogenous locus in mammalian cells. Proc Natl Acad Sci U S A 1987; 84: 9103-9107
74. Brash DE, Rudolph JA, Simon JA, A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991; 88: 10124-10128
75. Barnes DM, Hanby AM, Gillett CE, Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992; 340: 259-263
76. Lehman TA, Bennett WP, Metcalf RA, p53 Mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51: 4090-4096
77. Malkin D, Jolly KW, Barbier N, Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. N Engl J Med 1992; 326: 1309-1315
78. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747-749
79. Li FP Familial cancer syndromes and clusters. Curr Probl Cancer 1990; 14: 73-114
80. Toguchida J, Yamaguchi T, Dayton SH, Prevalence and spectrum of germline mutations of the p53 gene among patients with sarcoma. N Engl J Med 1992; 326: 1301-1308
81. Borresen AL, Andersen TI, Garber J, Screening for germ line TP53 mutations in breast cancer patients. Cancer Res 1992; 52: 3234-3236
82. Frebourg T, Barbier N, Kassel J, Ng YS, Romero P, Friend SH A functional screen for germ line p53 mutations based on transcriptional activation. Cancer Res 1992; 52: 6976-6978
83. Ishioka C, Frebourg T, Yan YX, et al. Screening patients for heterozygous p53 mutations using a functional assay in yeast. Nat Genet (in press).
84. Li FP, Garber JE, Friend SH, Recommendations on predictive testing for germ line p53 mutations among cancer-prone individuals. J Natl Cancer Inst 1992; 84: 1156-1160
85. Hall PA, Ray A, Lemoine NR, Midgley CA, Krausz T, Lane DP p53 Immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991; 338: 513-513
86. Bennett WP, Hollstein MC, He A, Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. Oncogene 1991; 6: 1779-1784
87. Maesawa C, Tamura G, Suzuki Y, Ishida K, Saito K, Satodate R Sensitive detection of p53 gene mutations in esophageal endoscopic biopsy specimens by cell sorting combined with polymerase chain reaction single-strand conformation polymorphism analysis. Jpn J Cancer Res 1992; 83: 1253-1256
88. Bennett WP, Hollstein MC, Metcalf RA, p53 Mutation and protein accumulation during multistage human esophageal carcinogenesis. Cancer Res 1992; 52: 6092-6097
89. Vahakangas KH, Samet JM, Metcalf RA, Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339: 576-580
90. Sozzi G, Miozzo M, Donghi R, Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992; 52: 6079-6082
91. Fearon ER, Vogelstein B A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-767
92. Wang LD, Hong JY, Qiu SL, Gao H, Yang CS Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. Cancer Res 1993; 53: 1783-1787
93. Sidransky D, Mikkelsen T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B Clonal expansion of p53 mutant cells is associated with brain tumour progression. Nature 1992; 355: 846-847
94. Crook T, Vousden KH Properties of p53 mutations detected in primary and secondary cervical cancers suggest mechanisms of metastasis and involvement of environmental carcinogens. EMBO J 1992; 11: 3935-3940
95. Ito T, Seyama T, Mizuno T, Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 1992; 52: 1369-1371
96. Sidransky D, Tokino T, Hamilton SR, Identification of ras oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992; 256: 102-105
97. Crawford LV, Pim DC, Bulbrook RD Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982; 30: 403-408
98. Caron de Fromentel C, May-Levin F, Mouriesse H, Lemerle J, Chandrasekaran K, May P Presence of circulating antibodies against cellular protein p53 in a notable proportion of children with B-cell lymphoma. Int J Cancer 1987; 39: 185-189
99. Davidoff AM, Iglehart JD, Marks JR Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 1992; 89: 3439-3442
100. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992; 52: 4168-4174
101. Schlichtholz B, Legros Y, Gillet D, The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52: 6380-6384
102. Thor AD, Moore DH II, Edgerton SM, Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-855
103. Iwaya K, Tsuda H, Hiraide H, Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991; 82: 835-840
104. Allred DC, Clark GM, Elledge R, Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 200-206
105. Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 1992; 52: 4828-4831
106. Thorlacius S, Borreson AL, Eyfjord JE Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993; 53: 1637-1641
107. Marchetti A, Buttitta F, Merlo G, p53 Alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 1993; 53: 2846-2851
108. Martin HM, Filipe MI, Morris RW, Lane DP, Silvestre F p53 Expression and prognosis in gastric carcinoma. Int J Cancer 1992; 50: 859-862
109. Isola J, Visakorpi T, Holli K, Kallioniemi OP Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. J Natl Cancer Inst 1992; 84: 1109-1114
110. Silvestrini R, Benini E, Daidone MG, p53 As an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 1993; 85: 965-970
111. Thor AD, Yandell DW Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. J Natl Cancer Inst 1993; 85: 176-177
112. Borresen AL, Helland A, Nesland J, Holm R, Trope C, Kaern J Papillomaviruses, p53, and cervical cancer. Lancet 1992; 339: 1350-1351 [Erratum, Lancet 1992;340:318.]
113. Soini Y, Paakko P, Nuorva K, Kamel D, Lane DP, Vahakangas K Comparative analysis of p53 protein immunoreactivity in prostatic, lung and breast carcinomas. Virchows Arch A Pathol Anat Histopathol 1992; 421: 223-228
114. Visakorpi T, Kallioniemi OP, Heikkinen A, Koivula T, Isola J Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J Natl Cancer Inst 1992; 84: 883-887
115. Riou G, Le MG, Favre M, Jeannel D, Bourhis J, Orth G Human papillomavirus-negative status and c-myc gene overexpression: independent prognostic indicators of distant metastasis for early-stage invasive cervical cancers. J Natl Cancer Inst 1992; 84: 1525-1526
116. Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990; 63: 1129-1136
117. Baker SJ, Fearon ER, Nigro JM, Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989; 244: 217-221
118. Laurent-Puig P, Olschwang S, Delattre O, Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992; 102: 1136-1141
119. Kern SE, Fearon ER, Tersmette KW, Clinical and pathological associations with allelic loss in colorectal carcinoma. JAMA 1989; 261: 3099-3103 [Erratum, JAMA 1989;262:1952.]
120. Olumi AF, Tsai YC, Nichols PW, Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinomas of the bladder. Cancer Res 1990; 50: 7081-7083
121. Sato T, Tanigami A, Yamakawa K, Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. Cancer Res 1990; 50: 7184-7189
122. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 1990; 249: 912-915
123. Casey G, Lo-Hsueh M, Lopez ME, Vogelstein B, Stanbridge EJ Growth suppression of human breast cancer cells by the introduction of a wild-type p53 gene. Oncogene 1991; 6: 1791-1797
124. Chen YM, Chen PL, Arnaiz N, Goodrich D, Lee WH Expression of wild-type p53 in human A673 cells suppresses tumorigenicity but not growth rate. Oncogene 1991; 6: 1799-1805
125. Johnson P, Gray D, Mowat M, Benchimol S Expression of wild-type p53 is not compatible with continued growth of p53-negative tumor cells. Mol Cell Biol 1991; 11: 1-11
126. Mercer WE, Shields MT, Amin M, Negative growth regulation in a glioblastoma tumor cell line that conditionally expresses human wild-type p53. Proc Natl Acad Sci U S A 1990; 87: 6166-6170
127. Puisieux A, Ponchel F, Ozturk M p53 As a growth suppressor gene in HBV-related hepatocellular carcinoma cells. Oncogene 1993; 8: 487-490
128. Felley-Bosco E, Weston A, Cawley HM, Bennett WP, Harris CC Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. Am J Hum Genet 1993; 53: 752-759
129. Diller L, Kassel J, Nelson CE, p53 Functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772-5781
130. Friedmann T Gene therapy of cancer through restoration of tumor-suppressor functions? Cancer 1992; 70: Suppl: 1810-1817
131. Dittmer D, Pati S, Zambetti G, Gain of function mutations in p53. Nat Genet 1993; 4: 42-46
132. Gerwin BI, Spillare E, Forrester K, Mutant p53 can induce tumorigenic conversion of human bronchial epithelial cells and reduce their responsiveness to a negative growth factor, transforming growth factor beta 1. Proc Natl Acad Sci U S A 1992; 89: 2759-2763
133. Robertson M Antigen processing: proteasomes in the pathway. Nature 1991; 353: 300-301
134. Hunt DF, Henderson RA, Shabanowitz J, Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. Science 1992; 255: 1261-1263
135. Yanuck M, Carbone DP, Pendleton CD, A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993; 53: 3257-3261
136. Chin KV, Ueda K, Pastan I, Gottesman MM Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 1992; 255: 459-462